{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:33:30Z","timestamp":1770910410677,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clinthera.2013.07.332","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T15:18:21Z","timestamp":1377184701000},"page":"1099-1107","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the Unstable Plaque in Acute Coronary Syndromes"],"prefix":"10.1016","volume":"35","author":[{"given":"Peter L.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Mark","family":"Nidorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.07.332_sbref1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM198405033101801","article-title":"Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death","volume":"310","author":"Davies","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.07.332_sbref75","doi-asserted-by":"crossref","first-page":"6J","DOI":"10.1161\/01.CIR.74.1.6","article-title":"Anatomic-physiologic links between acute coronary syndromes","volume":"74","author":"Gorlin","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","article-title":"Stability and instability: two faces of coronary atherosclerosis","volume":"94","author":"Davies","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","article-title":"Atherothrombosis and high-risk plaque: part I: evolving concepts","volume":"46","author":"Fuster","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis: an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.atherosclerosis.2011.10.018","article-title":"Association of coronary plaque composition and arterial remodelling: a optical coherence tomography study","volume":"221","author":"Rathore","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.07.332_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2012.10.054","article-title":"Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques","volume":"61","author":"Narula","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0008-6363(98)00212-0","article-title":"Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture","volume":"41","author":"Bennett","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2013.07.332_bib8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1172\/JCI117619","article-title":"Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques","volume":"94","author":"Galis","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.07.332_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.07.332_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.hco.0000181482.99067.bf","article-title":"The pleiotropic effects of statins","volume":"20","author":"Calabr\u00f2","year":"2005","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.102.8.846","article-title":"Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease","volume":"102","author":"Vita","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib13","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/01.CIR.99.25.3227","article-title":"Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial","volume":"99","author":"Dupuis","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction Investigators","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11936-012-0221-6","article-title":"LDL lowering after acute coronary syndrome: is lower better?","volume":"15","author":"Reddy","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","article-title":"The failure of torcetrapib: was it the molecule or the mechanism?","volume":"27","author":"Tall","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib18","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","article-title":"High-density lipoprotein as a therapeutic target: a systematic review","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib20","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib21","unstructured":"ETC-216 phospholipid. Drug developmenttechnology.com http:\/\/www.drugdevelopment-technology.com\/projects\/etc\/. Accessed May 10, 2013."},{"key":"10.1016\/j.clinthera.2013.07.332_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib23","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrcardio.2010.200","article-title":"Novel HDL-directed pharmacotherapeutic strategies","volume":"8","author":"deGoma","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2010.08.018","article-title":"Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?","volume":"4","author":"Tardif","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib26","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1258\/vasc.2011.201202","article-title":"Matrix metalloproteinases in vascular physiology and disease","volume":"20","author":"Siefert","year":"2012","journal-title":"Vascular"},{"key":"10.1016\/j.clinthera.2013.07.332_bib29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.ATV.16.8.1070","article-title":"Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis: implications for plaque rupture","volume":"16","author":"Lee","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.coph.2007.02.003","article-title":"Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine?","volume":"7","author":"MacFadyen","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0008-6363(98)00279-X","article-title":"Strategies to achieve coronary arterial plaque stabilization","volume":"41","author":"Rabbini","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2013.07.332_bib32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinthera.2013.07.332_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2012.12.001","article-title":"C-reactive protein and atherothrombosis: cause or effect?","volume":"27","author":"Grad","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2013.07.332_bib34","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.ATV.0000169644.88847.28","article-title":"CRP or not CRP? That is the question","volume":"25","author":"Pepys","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/01.CIR.0000139338.12464.5F","article-title":"Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study","volume":"110","author":"Bogaty","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib36","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","article-title":"Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial","volume":"372","author":"Baron","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.07.332_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nature04672","article-title":"Targeting C-reactive protein for the treatment of cardiovascular disease","volume":"440","author":"Pepys","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2013.07.332_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.07.332_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hlc.2012.12.002","article-title":"Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure","volume":"22","author":"Javed","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.clinthera.2013.07.332_bib40","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.07.332_bib42","first-page":"229","article-title":"TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?","volume":"13","author":"Park","year":"2012","journal-title":"Discov Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/art.30654","article-title":"Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis","volume":"64","author":"Ljung","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.07.332_bib44","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.0000158479.58589.0A","article-title":"Inflammatory markers at the site of ruptured plaque in acute myocardial infarction","volume":"11","author":"Maier","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.07.332_bib46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14712598.5.5.683","article-title":"The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody","volume":"5","author":"Mihara","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clinthera.2013.07.332_bib47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.07.332_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-9-8","article-title":"Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)","volume":"9","author":"Crossman","year":"2008","journal-title":"Trials"},{"key":"10.1016\/j.clinthera.2013.07.332_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.coi.2009.12.004","article-title":"The inflammasomes: mechanisms of activation and function","volume":"22","author":"Latz","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07853890.2010.546362","article-title":"The CD40-CD40L system incardiovascular disease","volume":"43","author":"Pamukcu","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2013.07.332_bib51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2009.03.076","article-title":"TheCD40\/CD40 ligand system: linking inflammation with atherothrombosis","volume":"54","author":"Antoniades","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.ATV.0000160340.72641.87","article-title":"Nuclear factor kappaB signaling in atherogenesis","volume":"25","author":"De Winther","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2011.03.025","article-title":"The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease","volume":"128","author":"Pamukcu","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2013.07.332_bib54","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4161\/cc.5.11.2773","article-title":"Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease","volume":"5","author":"Fraser","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clinthera.2013.07.332_bib55","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2174\/138955706777934937","article-title":"Naturally occurring NF-kappaB inhibitors","volume":"6","author":"Nam","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.clinthera.2013.07.332_bib56","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.4049\/jimmunol.0802972","article-title":"Antigen-specific suppression of inflammatory arthritis using liposomes","volume":"182","author":"Capini","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib57","doi-asserted-by":"crossref","unstructured":"Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis. 1983;3:178\u2013182","DOI":"10.1161\/01.ATV.3.2.178"},{"key":"10.1016\/j.clinthera.2013.07.332_bib58","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.07.332_sbref59","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2013.07.332_sbref76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol crystals and inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinthera.2013.07.332_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sca.4950280101","article-title":"Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events\u2014a novel insight into plaque rupture by scanning electron microscopy","volume":"28","author":"Abela","year":"2006","journal-title":"Scanning"},{"key":"10.1016\/j.clinthera.2013.07.332_bib61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacl.2010.03.003","article-title":"Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation","volume":"4","author":"Abela","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib62","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1161\/CIRCULATIONAHA.105.540013","article-title":"Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events","volume":"114","author":"Waxman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.07.332_bib63","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","article-title":"Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial","volume":"381","author":"Smits","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.07.332_bib64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2013.07.332_bib65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ahj.2011.07.018","article-title":"Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome","volume":"162","author":"O'Donoghue","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2013.07.332_bib66","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0140-6736(00)02222-4","article-title":"Dijkmans BAC. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular co-morbidity","volume":"355","author":"Landew\u00e9","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.07.332_bib68","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2013.07.332_bib69","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.07.332_bib70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)","volume":"7","author":"Ridker","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2013.07.332_bib71","unstructured":"Lowry F. FDA Panel says no to canakinumab for gout attacks. http:\/\/www.medscape.com\/viewarticle\/745076. Accessed May 10, 2013."},{"key":"10.1016\/j.clinthera.2013.07.332_bib72","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2013.07.332_bib73","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2013.07.332_bib74","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813007194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813007194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T18:06:53Z","timestamp":1563732413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813007194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0149291813007194"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.07.332","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}